<DOC>
	<DOCNO>NCT01778907</DOCNO>
	<brief_summary>Depression common among elderly estimate prevalence 5 % . Due age national burden double come decade . Antidepressants TCAs SSRIs effective reducing symptom , especially people severe depression . To optimize treatment efficacy reduce side effect , Pharmacogenetics Working Group Royal Dutch Pharmacists Association develop guideline dose-adaptation , instance antidepressant nortriptyline venlafaxine base main relevant genotype ( CYP2D6 ) accompany Therapeutic Drug Monitoring . Such personalized drug dose base pharmacogenetic information start therapy speed titration phase antidepressant establish adequate maintenance dose . However , pharmacogenetic screening program expensive evidence effect cost program among elderly antidepressant starter randomize controlled study lack . The investigator conduct pragmatic randomize control trial determine effect cost pharmacogenetic screen information optimize drug dose depress elderly patient start nortriptyline venlafaxine . Objective : The primary objective determine effect pharmacogenetic screen CYP2D6 time reach adequate blood level accept proxy adequate treatment . Secondary objective include adverse drug reaction cost-effectiveness Study design : pragmatic randomized control intervention study</brief_summary>
	<brief_title>Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants ( CYSCE )</brief_title>
	<detailed_description>This study multicenter randomize control trial psychiatric elderly care center participate Netherlands . Deviating genotype expect found ~30 % population , therefore study consist two part . First basic study ~750 patient , start nortriptyline venlafaxine genotyped identify patient deviate genotype ( Poor , Intermediate Ultrarapid Metabolizers ) . Second main study 150 patient deviate genotype randomly allocate two study arm one one without information genotype . From extensive metabolizers ( 'normal'genotype ) 75 patient allocated third arm external control .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<mesh_term>Antidepressive Agents , Tricyclic</mesh_term>
	<mesh_term>Antidepressive Agents , Second-Generation</mesh_term>
	<criteria>Major depression accord DSMIV ( 296.2x , 296.3x ) criterion treat psychiatrist decide start drug treatment either nortriptyline venlafaxine . Competent understand inform consent procedure Use clinically relevant CYP2D6 inhibitor Use clinically relevant CYP2D6 inducer Use drug affect plasma level comedication Serious hepatic failure Patients drug treatment venlafaxine start GFR &lt; 30 ml/min . Patients rare genotype : Intermediate Metabolizer duplication ( IMDUP ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Depression</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Cytochrome P-450 CYP2D6</keyword>
	<keyword>Antidepressive Agents , Tricyclic</keyword>
	<keyword>Antidepressive Agents , Second-Generation</keyword>
	<keyword>Poor Metabolizer Due Cytochrome P450 CYP2D6 Variant</keyword>
	<keyword>Intermediate Metabolizer Due Cytochrome P450 CYP2D6 Variant</keyword>
	<keyword>Ultrarapid Metabolizer Due Cytochrome P450 CYP2D6 Variant</keyword>
	<keyword>Multicenter study</keyword>
</DOC>